Investors

 

Key to long-term value: discipline, execution and consistent communication.

Print pageEmail pageRSS feedsShare page

Corporate Profile

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts is an integrated oncology company focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.

NASDAQ : ARIA (Common Stock)
$10.25 + 0.05
Stock chart for: ARIA.O
08/26/16 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.